OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion.
about
Dual role of prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissueCould a simple surgical intervention eliminate HIV infection?Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional CurePost-transcriptional gene silencing, transcriptional gene silencing and human immunodeficiency virusGenetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure?Achieving HIV-1 Control through RNA-Directed Gene RegulationDepletion of latent HIV-1 infection in vivo: a proof-of-concept studyEpigenetic regulation of HIV-1 latency by cytosine methylationActivation of latent HIV using drug-loaded nanoparticlesAn in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patientsDesigned, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitroLow-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART.Isolation of a cellular factor that can reactivate latent HIV-1 without T cell activation.Novel mechanistic insights into viral modulation of immune receptor signaling.CpG methylation controls reactivation of HIV from latency.Small-molecule screening using a human primary cell model of HIV latency identifies compounds that reverse latency without cellular activationCombinatorial latency reactivation for HIV-1 subtypes and variantsBET bromodomain inhibition as a novel strategy for reactivation of HIV-1Rational design of drugs that induce human immunodeficiency virus replication.Selective histonedeacetylase inhibitor M344 intervenes in HIV-1 latency through increasing histone acetylation and activation of NF-kappaBThe SCHOOL of nature: III. From mechanistic understanding to novel therapiesHexamethylbisacetamide remodels the human immunodeficiency virus type 1 (HIV-1) promoter and induces Tat-independent HIV-1 expression but blunts cell activationInnate and adaptive factors regulating human immunodeficiency virus type 1 genomic activation.Pharmaceutical approaches to eradication of persistent HIV infection.Histone deacetylase inhibitors for purging HIV-1 from the latent reservoir.High-throughput screening uncovers a compound that activates latent HIV-1 and acts cooperatively with a histone deacetylase (HDAC) inhibitor.Promoter Targeting RNAs: Unexpected Contributors to the Control of HIV-1 Transcription.Protein Kinase C: One Pathway towards the Eradication of Latent HIV-1 Reservoirs.Bryostatin activates HIV-1 latent expression in human astrocytes through a PKC and NF-ĸB-dependent mechanismActivation and lysis of human CD4 cells latently infected with HIV-1Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.IL-7 as a potential therapy for HIV-1-infected individuals.Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation.Gnidimacrin, a Potent Anti-HIV Diterpene, Can Eliminate Latent HIV-1 Ex Vivo by Activation of Protein Kinase C β.CRISPR-mediated Activation of Latent HIV-1 ExpressionHIV reservoirs and latency models.The role of cytokines in the establishment, persistence and eradication of the HIV reservoirCellular reservoirs of HIV-1 and their role in viral persistence.Reactivation of latent HIV-1 in central memory CD4⁺ T cells through TLR-1/2 stimulation.Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency
P2860
Q24562082-40B8741E-15A6-4531-AC61-3E8334E9AEEBQ24805899-F666AD7C-4348-4D8D-8AC1-27FD951F809BQ26781275-DE40572F-4CF9-419F-8014-BCFC30190074Q26797870-38E7D937-374C-4C18-939B-E649BCBF71CFQ26995220-AB73D596-CAEE-4C56-BAFA-DFE7D299B749Q28080090-F3FB34D7-31BC-45F8-88BB-3FAF15FCBB0CQ28111910-2384E8AB-0F8C-4705-8D32-0280D24A90D6Q28475636-D45EC3A1-6450-4562-9051-DB8790E850ECQ28477657-B91B6BEE-83F4-4BA5-A4FD-E401D69E3277Q28538015-A347C09E-49F1-421D-9CF9-38457895BBCDQ30558754-721EF17F-DCE3-454E-9534-71F5825C6945Q33313038-2FB17350-0E33-416F-A848-E682BBB01F73Q33425135-5E6A9603-C626-4264-BAFB-A37010B2BC63Q33489627-FB5F0844-AF53-4AE9-819D-1687B96C58CBQ33495565-F44D9B8B-4102-4B0B-8751-B6DEE285D854Q33508788-AC0CF41D-6DFB-485B-8189-698E3799E7ECQ33877492-161ED5E2-FA7E-4605-BEF5-2FCFADC64171Q34032827-CC9D3956-6168-4FC0-B76B-899CFCE6951BQ34229958-2C5D92CC-3895-4101-AA55-8A3DA2A9CDA0Q34482017-80D21729-53A3-4C9B-960A-9AE1B676C9F9Q34619705-5134D079-100F-4359-8751-7BC1B7E7D3EFQ34647406-9C217045-68C2-4833-B211-847E1CABCD30Q34671609-E2A69948-692F-4121-9FC0-C769A66BCBBAQ34941973-AC3AAB08-8979-40D7-AAB0-C172431B189FQ35016964-0DF971CF-240E-4D24-BE68-62710D755726Q35065109-76593616-2136-4396-87C1-212F95F39FF9Q35133922-78CE286C-B46A-4451-AF72-121C5E776AD4Q35830264-91C2DAA9-2292-4A93-B0DD-FADAF628D831Q35877276-26315D47-7A64-48EB-9470-3D79C77FB3ECQ36250921-31C6249A-5321-41BB-838A-47F66F09CA51Q36266486-053BE677-8F62-43D4-A082-E397FBFD750BQ36299926-BAE605FA-139F-4822-9A73-653CCFB22395Q36409885-3D8C845B-978C-4635-B634-1F56BF694D2FQ36617991-F982E9A5-916D-434A-9D8B-3D8F91077F3FQ36675297-5DB1417B-2FD7-4506-BF46-4144C50346A4Q36746403-36600FF8-44DB-4C13-8731-891486A91C46Q37157209-ADD5C8EA-16E2-42BC-BDE1-B35A18DAA270Q37196089-D46AEA3F-3D9C-45C6-95F3-AD0F2BB5B63CQ37305160-3CBF4D80-CF6B-466E-8748-232A3B3F8435Q37419972-449AB984-CC3C-494E-B042-6CF5CC06E42F
P2860
OKT3 and IL-2 treatment for purging of the latent HIV-1 reservoir in vivo results in selective long-lasting CD4+ T cell depletion.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
OKT3 and IL-2 treatment for pu ...... lasting CD4+ T cell depletion.
@en
OKT3 and IL-2 treatment for pu ...... lasting CD4+ T cell depletion.
@nl
type
label
OKT3 and IL-2 treatment for pu ...... lasting CD4+ T cell depletion.
@en
OKT3 and IL-2 treatment for pu ...... lasting CD4+ T cell depletion.
@nl
prefLabel
OKT3 and IL-2 treatment for pu ...... lasting CD4+ T cell depletion.
@en
OKT3 and IL-2 treatment for pu ...... lasting CD4+ T cell depletion.
@nl
P2093
P356
P1476
OKT3 and IL-2 treatment for pu ...... lasting CD4+ T cell depletion.
@en
P2093
A J Eerenberg
H Schuitemaker
I J Ten Berge
J Goudsmit
P2888
P304
P356
10.1023/A:1011091300321
P577
2001-05-01T00:00:00Z